Real‐world persistence of multiple sclerosis disease‐modifying therapies

Tallantyre, Emma C.; Dobson, Ruth; Froud, Joseph L. J.; St John, Frederika A.; Anderson, Valerie M.; Arun, Tarunya; Buckley, Lauren; Evangelou, Nikos; Ford, Helen L.; Galea, Ian; George, Sumi; Gray, Orla M.; Hibbert, Aimee M.; Hu, Mo; Hughes, Stella E.; Ingram, Gillian; Kalra, Seema; Lim, Chia‐Hui E.; Mathews, Joela T. M.; McDonnell, Gavin V.; Mescall, Naomi; Norris, Sam; Ramsay, Stephen J.; Rice, Claire M.; Russell, Melanie J.; Shawe‐Taylor, Marianne J.; Williams, Thomas E.; Harding, Katharine E.; Robertson, Neil P.

doi:10.1111/ene.16289

All Outputs (2)

Demographic trends of motor neurone disease-associated mortality from 1999-2020 in the United States [version 1; peer review: awaiting peer review] (2024)
Journal Article
Imantalab, D., Singh Sokhal, B., Prasanna Kumar Menon, S., Kalra, S., Muller, S., & Mallen, C. (2024). Demographic trends of motor neurone disease-associated mortality from 1999-2020 in the United States [version 1; peer review: awaiting peer review]. NIHR Open Research, 1-14. https://doi.org/10.3310/nihropenres.13786.1

Motor Neurone Disease (MND) is a neurodegenerative condition affecting motor neurons in spinal cord and brainstem, leading to a reduced life expectancy. This study describes demographic trends in MND-associated mortality in the United States over a 2... Read More about Demographic trends of motor neurone disease-associated mortality from 1999-2020 in the United States [version 1; peer review: awaiting peer review].

Real‐world persistence of multiple sclerosis disease‐modifying therapies (2024)
Journal Article
Tallantyre, E. C., Dobson, R., Froud, J. L. J., St John, F. A., Anderson, V. M., Arun, T., …Robertson, N. P. (in press). Real‐world persistence of multiple sclerosis disease‐modifying therapies. European Journal of Neurology, Article e16289. https://doi.org/10.1111/ene.16289

Background and purpose: Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real‐world rates of persistence on disease‐modifying therapies (DMTs) for p... Read More about Real‐world persistence of multiple sclerosis disease‐modifying therapies.